The anti-PD-L1 monoclonal antibody (mAb) atezolizumab improved response rate (RR) (56.0% with ICI vs. 45.9% with placebo), progression-free survival (PFS) (HR 0.62; 95% CI, 0.49–0.78), and overall survival (OS) (HR 0.62; 95% CI, 0.45–0.86) when added to nab-paclitaxel in patients with PDL-1-positive immune cells covering 1% or greater of the tumour area using the companion diagnostic assay (Ventana PD-L1 SP142) [25]. The gene discussed is CD274; the disease is neoplasm.